Skip to content
OpenCapital
Get started

SION SION Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number at other companies

Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
——

Other financials

Income statement

See full
Operating income-$29.6M-50.6%
Net income-$26.8M-62.5%
EPS (diluted)-$0.60+3.2%

Balance sheet

See full
Cash & equivalents$64.3M-23.2%
Total debt$8.4M-11.8%
Total equity$288.2M-18.1%
Total assets$305.0M-17.5%

Cash flow

See full
Operating cash flow-$21.8M-34.1%
CapEx--100%
Free cash flow-$21.8M-33.4%

Valuation

See full
Market cap$1.86B—

Returns & leverage

See full
Return on equity-26.7%—
Debt / equity0×0.0×
Current ratio22.6×-6.1×

Where this comes from

Reported directly by SION in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: SION’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SION's share-based compensation arrangement by share-based payment award, options, outstanding, number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SION's share-based compensation arrangement by share-based payment award, options, outstanding, number?
SION (SION) reported share-based compensation arrangement by share-based payment award, options, outstanding, number of $7.13M in Q1 2026.
How has SION's share-based compensation arrangement by share-based payment award, options, outstanding, number changed year-over-year?
SION's share-based compensation arrangement by share-based payment award, options, outstanding, number increased by 26.1% year-over-year, from $5.65M to $7.13M.